Home › Sovrappeso › Michigan
Studi clinici su Sovrappeso nello stato di Michigan
19 studi su Sovrappeso cercano partecipanti presso sedi nello stato di Michigan.
Città nello stato di Michigan
Testo ufficiale dello studio (inglese)
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Northern Pines Hlth Ctr, PC, Buckley
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07720271Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Profound Research, Farmington Hills
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07837973A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Great Lakes Research Group, Inc., Bay City
- Great Lakes Research Institute, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Aa Mrc Llc, Flint
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07595549A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Helen Devos Childrens' Hospital - PIN, Grand Rapids
In reclutamentoFase 3
Età da 6 a 17 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07321886A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Great Lakes Research Institute, Southfield
- Revive Research Institute, Inc., Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07392190A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Revive Research Institute, Inc., Southfield
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07369011A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07589608A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Farmington Hills
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07784270A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Southfield
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743450A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- David Fivenson, MD, PLC, Ann Arbor
- The Derm Institute of West Michigan, Caledonia
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06857942Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Headlands Research - Detroit, Southfield
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07684235Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Farmington Hills
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07284901Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division, Troy
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Troy
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT07784725AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Arcturus Healthcare, PLC., Troy
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Ann Arbor
In reclutamentoFase 3
Età da 18 a 79 · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT07654361Fonte: ClinicalTrials.gov, dati recuperati il 2 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.